title: Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: B
authors.initials: B
authors.lastname: Guiducci
authors.forename: F
authors.initials: F
authors.lastname: D'Adamo
authors.forename: A
authors.initials: A
authors.lastname: Mele
authors.forename: G
authors.initials: G
authors.lastname: Nicolini
authors.forename: G
authors.initials: G
authors.lastname: Leopardi
authors.forename: G
authors.initials: G
authors.lastname: Sparaventi
authors.forename: S
authors.initials: S
authors.lastname: Barulli
authors.forename: L
authors.initials: L
authors.lastname: Malerba
authors.forename: A
authors.initials: A
authors.lastname: Isidori
authors.forename: M
authors.initials: M
authors.lastname: Malagola
authors.forename: P P
authors.initials: PP
authors.lastname: Piccaluga
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone